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Abstract
Backgrounds: Glycoprotein 2[GP2] and CUB zona pellucida-like domain 1[CUZD1] belong to protein 
families involved in gut innate immunity processes and have recently been identified as specific targets 
of anti-pancreatic autoantibodies [PAbs] in Crohn’s disease[CD]. We aimed to determine the prognostic 
potential of novel target-specific PAbs regarding long-term disease course of an adult CD patient cohort.
Methods: Sera of 458 consecutive well-characterised IBD patients from a single referral 
IBD centre were tested by enzyme-linked immunosorbent assay [ELISA] with isoform 4 of 
recombinant GP2 [anti-MZGP2 and anti-GP2 IgA/IgG] and indirect immunofluorescence test 
[IIFT] system with GP2 and CUZD1 expressing transfected HEK 293 cells [anti-rPAg2 and rPAg1 
IgA/IgG]. Clinical data were available on complicated disease or surgical interventions as well as 
disease activity and medical treatment during the prospective follow-up [median, 108 months].
Results: Totals of 12.4% and 20.8% of CD patients were positive for IgA/IgG type of anti-
GP2 and anti-CUZD1, respectively, with a significant difference compared with UC [p < 0.01]. 
Antibody status was stable over time. Agreement among three different anti-GP2 assays 
was good. Positivity for PAbs, mainly IgA subtypes, predicted a faster progression towards 
complicated disease course. In Kaplan-Meier analysis, time to surgery or development of 
perianal disease was associated with anti-GP2 IgA [pLogRank < 0.01] or anti-CUZD1 IgA 
[pLogRank < 0.001] positivity, respectively. Anti-CUZD1 IgA remained an independent 
predictor in the multivariate Cox-regression model (hazard ratio [HR]: 3.43, 95% confidence 
interval [CI]: 1.68–7.02, p < 0.001).
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Conclusions: The present study has shown that specific PAbs [especially IgA subtype] predict 
complicated disease course including the development of perianal disease in CD.
Keywords:  Serological antibodies; anti-pancreatic antibodies; glycoprotein CUZD1; glycoprotein 2; immunoglobulin A; Crohn’s disease; ulcerative 
colitis; disease progression
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1. Introduction
Inflammatory bowel diseases [IBD] are chronic inflammatory dis-
orders of the gastrointestinal tract. Both Crohn’s disease [CD] and 
ulcerative colitis [UC] are heterogeneous in their presentation and 
disease course. Serological antibodies have been reported to assist in 
the diagnosis, differential diagnosis, and prediction of either disease 
course or response to therapy in IBD.1 There is accumulating evi-
dence from cross-sectional, longitudinal studies and meta-analyses 
that support the value of serological markers in identifying patients 
with complicated disease phenotype and increased risk of surgery in 
patients with CD. Anti-Saccharomyces cerevisiae antibody [ASCA] 
has been identified as the most accurate single marker in CD as yet. It 
is questionable whether other markers can identify a specific subset 
of CD patients.2
Enhanced formation of autoantibodies against acinar cells of 
the exocrine pancreas in patients with CD and coeliac disease was 
reported.3 Presence of pancreatic autoantibodies [PAbs] was iden-
tified first by indirect immunofluorescence technique [IIFT],4 and 
human and primate pancreas substrate has been used as the pri-
mary diagnostic test for PAbs so far. PAbs are present in up to 40% 
of the patients with CD and can be used to differentiate CD from 
UC.2 Furthermore some studies, including the one with the largest 
patient cohort, have suggested that presence of PAbs is associated 
with specific disease phenotypes and their detection may be of clini-
cal significance.5,6
More recently, the target antigens of PAbs have been identi-
fied: the pancreatic major glycoprotein GP2 of the zymogen gran-
ule membrane and CUZD1 protein [CUB and zona pellucida-like 
domains 1].7,8 In the study of Komorowski et al., the authors verified 
that the formerly reported reticulogranular pattern in tissue sections 
of human pancreas by IIFT is strictly correlated with the presence 
of anti-CUZD1, whereas droplet pattern is correlated with the pres-
ence of anti-GP2 antibodies.9 Furthermore, investigation of GP2 and 
CUZD1 revealed that they belong to protein families involved in 
innate and adaptive immunity.10,11 Presumably GP2 and CUZD1 
may be involved in maintaining the balance between tolerance to 
commensal bacteria and immune response against pathogens.12
Identification of the autoantigens has facilitated the development 
of new diagnostic tools for evaluation of PAbs, such as enzyme-
linked immunosorbent assay [ELISA] with isoform 4 of recombinant 
GP213 or advanced CUZD1 and GP2 expressing cell-based IIFT.14 
Experience with these newly available techniques for PAb detec-
tion is scarce, especially on the clinical importance of PAbs in CD. 
Recombinant GP2-based ELISA systems were used primarily in these 
studies. In contrast, information about anti-CUZD1 is very limited.9 
Presence of anti-GP2 was associated with stricturing behaviour with 
perianal disease in some15,16,17 but not all studies.18 However, studies 
were limited by cross-sectional design. Longitudinal follow-up stud-
ies are needed to unravel the clinical importance of these antibodies 
in CD prognosis. For this, studies should also investigate long-term 
stability of PAbs
The primary aim of the present study was to determine the pre-
dictive potential of the different PAbs with regard to the develop-
ment of disease-specific complications or need for surgery in a large 
prospective referral CD cohort. The secondary aims were to investi-
gate: [1] the long-term stability of the PAbs response; [2] association 
of PAbs formation to the clinical, serological and genetic character-
istics of CD; and lastly [3] to define the agreement between the new 
diagnostic tools for the evaluation of different target-specific PAbs.
2. Material and Methods
2.1. Patient population
We performed a cohort study among adult CD and UC patients 
in one tertiary IBD referral centre of Hungary [Department of 
Gastroenterology, Institute of Internal Medicine, University of 
Debrecen]. In all, 458 well-characterised, unrelated, consecutive IBD 
patients with a complete clinical follow-up {CD: 271, male/female: 
120/140, median age at presentation: 25 years (inter quartile range 
[IQR], 19–33) and UC: 187, male/female: 86/101, median age at 
presentation, 33 years (IQR, 23–43])} seen at our outpatient clinic 
were included between January 1, 2005 and June 1, 2010.
The clinical characteristics of the patients at diagnosis are pre-
sented in Table  1. Diagnosis of IBD was based on the Lennard–
Jones criteria.19 The disease phenotype [age at onset, duration, 
location, and behaviour] was determined according to the Montreal 
Classification.20 Blood samples and detailed clinical phenotypes 
were captured at inclusion. Clinical data were determined by thor-
ough review of patients’ medical records, which had been collected 
in a uniform format. Medical records that documented the disease 
phenotype, presence of extraintestinal manifestations [EIM] (for 
example, arthritis: peripheral and axial; ocular manifestations: 
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conjunctivitis, uveitis, iridocyclitis; skin lesions: erythemanodosum, 
pyoderma gangrenosum; and hepatic manifestations: primary scle-
rosing cholangitis [PSC]), frequency of flare-ups [frequent flare-up: 
> 1 clinical relapse/year],21 medication use [eg steroid, immuno-
suppressive and/or biological use at any time], need for surgery 
[resection in CD and colectomy in UC], the presence of familial 
IBD, smoking habits, and perianal involvement were retrospec-
tively analysed for the period prior to the prospective follow-up. 
At enrolment, clinical disease activity was calculated according to 
the Harvey–Bradshaw Index [HBI]22 in CD and the partial Mayo 
score in UC.23 In this study we followed the ECCO [European 
Crohn’s and Colitis Organisation] guidelines24 and defined HBI ≤ 
4 as a state of remission and ≥ 5 as a state of active disease. In case 
of UC, ≤ 3 was defined as a state of remission and > 4 as a state 
of active disease. Endoscopic activity was determined according to 
the Simple Endoscopic Score for Crohn’s Disease [SES-CD] in CD25 
and the endoscopic component of the Mayo score in UC.26 SES-CD 
defines endoscopic activity ≥ 3 points and inactive disease ≤ 2 in CD, 
whereas in UC the state of active disease was defined as invasive 
partial Mayo score ≥ 1.
2.2. Phenotypical characterisation of CD patients 
during prospective follow-up
CD patients were enrolled into a prospective follow-up study, 
where the treating IBD physicians registered laboratory data, 
endoscopic and imaging findings, disease activity, medical treat-
ment, date and type of complications, and surgery during regu-
lar and extraordinary outpatient follow-up visits and inpatient 
stays. In Hungary, a follow-up visit is usually scheduled for every 
6 months at a specialised gastroenterology centre [the actual inter-
val varies between 3 and 6  months]. The treatment algorithms, 
both the medical and the surgical, are harmonised and followed 
the actual ECCO guidelines.24,2728,29,30 Need for surgery and tim-
ing of the resection is a consistent multidisciplinary decision with 
the collaboration of the gastroenterologist, radiologist, and sur-
geon. Collected data were transferred and stored in a database 
for analysis. In October 1, 2013, all patients’ charts and data-
base were reviewed and updated for the data points mentioned 
above. Follow-up for a particular patient was terminated if there 
was no further record available. Median follow-up from diagno-
sis was 108  months [IQR, 65–178]. In CD, complicated disease 
Table 1. Clinical characteristics of IBD patients.
CD [n = 271] UC [n = 187]
Male/female [n] 115/156 86/101
Age at presentation [years]a 25 [19–33] 33 [23–43]
Follow-up [months]a,b 108 [65–178] 104 [62–182]
Familial IBDc 12 [4.4%] 6 [3.2%]
Location/extent at diagnosisc
 L1 60 [22.1%] Proctitis30 [16.0%]
 L2 88 [32.5%] Left-sided 104 [55.6%]
 L3 122 [45.0%] Extensive 53 [28.3%]
 L4 only 1 [0.4%]
 All L4 16 [5.9%]
Behaviour at diagnosisc
 B1 216 [79.7%]
 B2 33 [12.2%]
 B3 22 [8.1%]
Perianal diseasec
 at diagnosis 49 [18.1]
 last follow-up⁭ 93 [35.1]
Cumulative exposure of medication and surgeries during follow-up
Steroid use/refractoryc 239 [88.2%] / 144 [77.0%]/
31 [13.0%]  11 [7.6%]
Azathioprine usec 200 [73.8%] 66 [35.3%]
Surgery/multiple in CD 109 [41.1%]/ 7 [3.7%]
Colectomy in UCc 31 [11.7%]
Biologicals usec 113 [41.7%] 25 [13.4%]
Smoking habitsc
 never 219 [80.8%] 167 [89.3%]
 yes 47 [17.3%] 18 [9.6%]
 previous 5 [1.8%] 2 [1.1%]
IBD, inflammatory bowel disease; UC, ulcerative colitis; CD, Crohn’s dis-
ease.
aMedian [IQR].
b265 CD patients had follow-up.
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Figure 1. Flow chart of the patients with Crohn’s disease [CD] in the cohort study. Event, complication and/or surgery; complication, stricture development and/
or internal penetration and/or perianal penetration; surgery, CD-related surgery [resection only]; Pts, patients.
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behaviour was defined as the occurrence of stenosis or internal 
penetration. Perianal fistulising disease was distinguished from 
internal penetrating disease and evaluated separately. Need for 
surgery was defined as CD-related abdominal surgery [resection]. 
Figure 1 summarises the flow chart of the patients with CD in the 
cohort study.
The control group consisted of 100 age- and gender-matched 
healthy blood donors (male/female: 46/54, median age at presenta-
tion, 30 years [IQR, 21–40]). The control subjects did not have any 
gastrointestinal and/or liver disease and were selected from consecu-
tive blood donors in Debrecen.
2.3. Serological analysis
Blood samples were obtained at enrolment from each patient and 
were frozen at -80°C until testing. All the serological assays were 
performed in a blinded fashion without prior knowledge of the 
patient’s diagnosis or other clinical information.
2.4. Detection of antibodies to GP2 by enzyme-
linked immunosorbent assays
Glycoprotein 2 autoantibodies were detected in sera of patients 
and controls using two different ELISAs employing recombinant 
human GP2 isoform 4 as solid-phase antigen (anti-MZGP2 IgA 
and IgG QUANTA Lite® ELISA [Inova Diagnostics, San Diego, CA, 
Research Use Only] and anti-GP2 IgA and IgG ELISA [GA Generic 
Assays, Dahlewitz/Berlin, Germany]) according to the manufac-
turers’ instructions. Briefly, 100 µl of pre-diluted sera [1:100] was 
added to separate wells of MZGP2 or GP2 antigen-coated polysty-
rene microwells and incubated for 30 min and 60 min, respectively, 
at room temperature. Unbounded sample was then washed away 
and peroxidase-conjugated goat anti-human IgA antibody or anti-
human IgG antibody was added to each well and developed with 
ready-to-use hydrogen peroxide / tetramethylbenzidine chromogenic 
substrate. The reaction was terminated with sulphuric acid and opti-
cal density of the samples was read at wavelength of 450/620 nm. 
Results expressed in arbitrary units [AU/ml], were calculated with 
reference to a kit-provided calibrator. Serum samples showing ≥ 25 
AU/ml for anti-MZGP2 and ≥ 20 AU/ml for anti-GP2, respectively, 
were interpreted as positive.
2.5. Detection of antibodies to GP2 and CUZD1 by 
indirect immunofluorescence tests
Anti-GP2 and anti-CUZD1 IgA and IgG were detected in sera of 
patients and controls using cell-based IIFT [Morbus-Crohn Mosaic 
1, Euroimmun Medizinische Labordiagnostika AG, Lübeck, 
Germany]. Biochips coated with transfected HEK293 cells, express-
ing GP2 and CUZD1 separately, are applied as substrates and were 
co-incubated with pre-diluted sera [1:10, 1:100, and 1:1000] for 
30 min at room temperature. Unbounded sample was then washed 
away and fluorescein-labelled goat anti-human IgA or IgG anti-
bodies were used to visualise bound antibodies of the patients’ 
sera. Evaluation was performed using a Eurostar Plus microscope 
with Bluelight LED [Euroimmun Medizinische Labordiagnostika 
AG]. Supplementary Figure 1 [available as Supplementary data at 
ECCO-JCC online] shows immunofluorescence staining patterns on 
HEK293 transfected with either CUZD1 or GP2. According to find-
ings of Komorowski et al.,9 reaction with transfected HEK293 cells 
expressing CUZD1 entirely corresponds to reticulogranular PAb 
pattern [type 1] on frozen sections of the human pancreas, whereas 
GP2-HEK reaction forms the droplet pattern [type 2].
2.6. Antibody assays for anti-Saccharomyces 
cerevisiae antibodies
ASCA antibody evaluation in CD patients was performed by ELISA 
[QUANTA LiteTM, Inova Diagnostics, San Diego, CA] according to 
the manufacturers’ instructions. The results are presented as arbi-
trary units, and values above the cut-off of 25 units were considered 
as positive. The results were documented in absolute values and in 
frequency of positivity.
2.7. Detection of NOD2/CARD15 SNP8, 12, 13 
mutations
NOD2/CARD15 SNP8, SNP12, and SNP13 genotypes were per-
formed previously31 in CD patients [n = 235], but not in UC patients. 
NOD2/CARD15 variants were detected by denaturing high-per-
formance liquid chromatography [dHPLC, Wave DNA Fragment 
Analysis System, Transgenomic, UK]. Sequence variation, observed 
in the dHPLC profile, was sequenced on both strands to confirm 
the alteration. Sequencing reactions were performed with the ABI 
BigDye Terminator Cycle Sequencing Kit v1.1 [Applied Biosystems, 
Foster City, CA] and samples were sequenced on an ABI Prism 310 
Genetic Analyzer [Applied Biosystems, Foster City, CA]. All inves-
tigated polymorphisms were in Hardy–Weinberg equilibrium [data 
not shown].
2.8. Ethical considerations
The regional and national committee (DEOEC RKEB/IKEB 3515-
2011, 3880/2012/EKU [59/PI/2012]) for research ethics approved 
the study protocol. Each patient was informed of the nature of the 
study and signed an informed consent form.
2.9. Statistical analysis
Variables were tested for normality using Shapiro Wilk’s W test. 
Continuous variables were summarized as means (standard devia-
tion [SD]) or as medians (interquartile range [IQR]) according to 
their homogeneity. To evaluate differences between IBD and the 
healthy control group, as well as within subgroups of patients with 
IBD, the following statistical methods were used. Categorical vari-
ables were compared with Fisher’s exact test or χ2 test with Yates 
correction, linear-by-linear association, as appropriate. Continuous 
variables were compared with Student’s t test, one-way analysis 
of variance [ANOVA], or MannWhitney’s U test or KruskalWallis 
H test with post hoc analysis [Dunn’s multiple comparison test]. 
Kaplan-Meier survival curves were plotted for analysing the associa-
tion between categorical clinical variables or serological antibodies 
and complicated disease outcomes during follow-up with LogRank 
testing or Cox-regression analysis in the time-dependent models. 
Associations are given as odds ratio [OR] and hazard ratio [HR] 
with a 95% confidence intervals [CI]. A 2-sided probability value 
< 0.05 was considered to be statistically significant. For statistical 
analysis, GraphPad Prism 6 [San Diego, CA] and SPSS 22.0 [SPSS, 
Chicago, IL] programs were used.
3. Results
3.1. Frequency of anti-pancreatic antibodies in IBD
The frequencies of the different antibodies in IBD and controls 
are summarised in Table  2. Significantly more, 10.2%, 12.2%, 
10.2%, and 20.8% of the CD patients were positive for anti-GP2 
IgA/IgG, anti-MZGP2 IgA/IgG, anti-rPAg2 IgA/IgG, and also for 
anti-CUZD1 [≈ anti-rPAg1] IgA/IgG antibodies compared with 
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both UC and healthy controls [p < 0.01 for all], respectively. In 
addition, significant differences were found for both IgA and IgG 
subtypes. In contrast, the positivity rate was not different in UC 
and controls.
Anti-GP2 and anti-MZGP2 antibody titres were higher in CD 
compared with UC. The difference of the median titres for all anti-
bodies, except anti-MZGP2 IgA, between CD and UC was statisti-
cally significant [MannWhitney, anti-GP2 IgA p < 0.001, anti-GP2 
IgG p  <  0.001, anti-MZGP2 IgA p  =  0.12, anti-MZGP2 IgG 
p < 0.001].
3.2. Correlation of anti-pancreatic antibodies 
formation and overall disease duration in Crohn’s 
disease: stability of anti-pancreatic antibodies in 
Crohn’s disease
No association was detected between antibody status and clinical 
or endoscopic disease activity [actual HBI or SES-CD] at the time of 
sample procurement [data not shown]. In addition, to evaluate the 
stability of PAb status [positive or negative for a respective antibody], 
we analysed samples from the same patient over various arbitrary 
time-points during the disease course. At least two serum samples 
were taken from each of the majority of CD patients [n = 192] and 
re-tested for all the different PAbs. Median time between sample 
procurements was 30.3 months [IQR, 15.3–48.7]. Interestingly, the 
status of different PAbs was very stable over time regarding both IgA 
and IgG subtypes, with only ≤ 5% of cases changing their PAb status 
over time. Stability data of PAbs are summarised in Supplementary 
Table  2 [available as Supplementary data at ECCO-JCC online]. 
Development of disease complications or surgical procedures did 
also not affect the antibody status of any of the PAbs [data not 
shown].
3.3. Predictive potential of anti-pancreatic 
antibodies for disease outcomes in Crohn’s disease
We analysed the association of the different PAb markers with poor 
disease outcomes [development of internal penetrating and/or stric-
turing disease, perianal perforating disease, and need for first and 
subsequent surgical resection] in time-dependent univariate models.
None of the PAb markers was able to predict the development of 
internal penetrating and/or stricturing complications in patients with 
inflammatory disease behaviour [B1] [n = 211].
Among patients without previous perianal complication [any 
behaviour] [n  =  216], those who were positive for anti-CUZD1 
IgA/IgG were more likely to progress to develop perianal complica-
tions [pLogRank = 0.008]. The association was stronger for the IgA 
antibody subtype [pLogRank < 0.001] and a quantitative associa-
tion was also found with IgA antibody titres [pLogRank < 0.001] 
[Figure  3]. The sensitivity analysis performed in patients with B1 
phenotype only behaviour [n = 169] after excluding patients with 
an initial B2/3 phenotype yielded the same results regarding the 
development of perianal complications [pLogRank < 0.001 for the 
anti-CUZD1 IgA].
In the surgery-naïve patient group [n = 234], progression to first 
resective surgery was faster in patients positive for anti-GP2 IgA 
antibody [pLogRank = 0.002] [Figure 2]. At the same time, in post-
operative settings, the presence of anti-GP2 IgA antibody was not 
able to predict a subsequent resective surgery in patients with previ-
ous surgery [n = 109].
To further evaluate the predictive potential of the PAb mark-
ers, we used a Cox-proportional hazard regression model adjusted 
to gender and clinical variables with a p-value of < 0.1 in univari-
ate time-dependent models [Kaplan-Meier and LogRank analy-
sis]. Anti-CUZD1 IgA and anti-GP2 IgA were analysed separately. 
Table 2. Serological markers in patients with Crohn’s disease, ulcerative colitis, and healthy controls.
CD UC HCONT
Anti-GP2 n = 266 Anti-GP2 n = 183 Anti-GP2 n = 100
Anti-MZGP2 n = 266 Anti-MZGP2 n = 185 Anti-MZGP2 n = 100
Anti-rPAg n = 264 Anti-rPAg n = 178 Anti-rPAg n = 100
Anti-GP2 IgG 27 [10.2%]☐,** 3 [1.6%]☐ 1 [1.0%]**
Anti-GP2 IgA 9 [3.4%]† 0 [0.0%]† 1 [1.0%]
Anti-GP2 either 27 [10.2%]☐,* 3 [1.6%]☐ 2 [2.0%]*
Anti-MZGP2 IgG 26 [9.8%]☐,§ 2 [1.1%]☐ 2 [2.0%]§
Anti-MZGP2 IgA 22 [8.3%]☐ 0 [0.0%]☐ 4 [4.0%]
Anti-MZGP2 either 33 [12.4%]☐ 2 [1.1%]☐ 6 [6.0%]
Anti-rPAg1 IgG 43 [16.3%]⌘ 12 [6.7%] 0 [0.0%]⌘
Anti-rPAg1 IgA 32 [12.1%]⌘ 11 [6.2%] 0 [0.0%]⌘
Anti-rPAg1 either 55 [20.8%]‡,⌘ 16 [9.0%]‡ 0 [0.0%]⌘
Anti-rPAg2 IgG 18 [6.8%]‡,** 0 [0.0%]‡ 0 [0.0%]**
Anti-rPAg2 IgA 19 [6.9%]‡,** 1 [0.6%]‡ 0 [0.0%]**
Anti-rPAg2 either 27 [10.2%]☐,⁭ 1 [0.6%]☐ 0 [0.0%]⁭
Anti-rPAg IgG 55 [20.8%]☐,⌘ 12 [6.7%]☐ 0 [0.0%]⌘
Anti-rPAg IgA 46 [17.4%]#,⌘ 12 [6.7%]# 0 [0.0%]⌘
Anti-rPAg either 73 [27.7%]☐,⌘ 17 [9.6%]☐ 0 [0.0%]⌘
UC, ulcerative colitis; CD, Crohn’s disease, HCONT, healthy controls.
Cut-off levels were 25 U/ml for anti-GP2, 20 U/ml for anti-MZGP2 by enzyme-linked immunosorbent assay, and 1:10 titre for anti-rPAg antibodies by indirect 
immunofluorescence assay. Anti-rPAgA1 and rPAgA2 correspond to anti-CUZD1 and anti-GP2, respectively.
CD vs controls: §p = 0.015, *p = 0.01, **p =< 0.01, ⁭p = 0.001,⌘p < 0.001.
CD vs UC: †p = 0.01, #p < 0.01, ‡p = 0.001, ⁭p < 0.001
using χ2-test with Yates correction.
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Anti-CUZD1 IgA was identified as an independent predictor for the 
development of perianal disease both in the primary model [Table 4] 
and in the model in the same sensitivity analysis [data not shown]. 
In contrast, the association between anti-GP2 and need for resective 
surgery was lost in the multivariate model [Table 4].
3.4. Association between anti-pancreatic antibody 
positivity and clinical, serological, and genetic 
characteristics of Crohn’s disease
Anti-MZGP2 IgA/IgG antibodies were more prevalent in patients 
with paediatric disease onset [A1: 28.6%, A2: 11.3%, A3: 5.7%, 
p = 0.012] and anti-rPAg2 IgA/IgG antibodies [L1/3 vs L2, 13.2% vs 
4.5%, p = 0.032] were more frequent in patients with ileal involve-
ment. Penetrating disease behaviour at last follow-up was associated 
with anti-GP2 IgA/IgG [17.9% vs 7.3%, p = 0.026], anti-MZGP2 
IgA/IgG [20.2% vs 8.9%, p = 0.040] and anti-rPAg2 IgA antibodies 
[13.1% vs 4.8%, p = 0.040]. In addition, anti-GP2 IgA/IgG [14.5% 
vs 6.6%, p = 0.036] was associated with need for resective surgery 
at maximum follow-up. Of the extraintestinal manifestations, anti-
rPAg2 IgA/IgG positivity was associated with PSC [37.5% vs 9.4%, 
p = 0.038]. In contrast, PAb directed against CUZD1 [≈anti-rPAg1] 
was associated with colonic involvement [L2/L3 vs L1, 23.7% vs 
10.5%, p = 0.041 for IgA/IgG subtype], perianal disease at maxi-
mum follow-up [P1 vs P0, 32.6% vs 15.0%, p = 0.001 for IgA/IgG 
subtype], and cutaneous manifestations [23.5% vs 10.4%, p = 0.044 
for IgA subtype]. Table 3 presents the associations between antibody 
reactivities to different PAbs and disease characteristics in patients 
with CD at diagnosis and maximum follow-up according to Ig sub-
types. There was an association between the presence of IgA type 
PAbs and ASCA antibodies. The different PAb IgA antibodies were 
significantly more frequent in ASCA IgA positives compared with 
negatives [anti-GP2 IgA: 6.7% vs 0.0%, anti-MZGP2 IgA: 14.6% vs 
1.7%, anti-rPAg1: 17.5% vs 4.9%, and anti-rPAg2: 11.7% vs 2.4%, 
p  <  0.01 for all]. However, PAb IgG positivity did not differ sig-
nificantly according to presence or absence of ASCA IgG [Table 3]. 
The prevalence of different PAbs was also not associated with the 
presence or absence of major NOD2/CARD15 mutations [data not 
shown].
3.5. Interassay study for anti-GP2 antibodies
Altogether, the agreement among the three different assays ranged 
from 94.0% to 95.6% for anti-GP2 IgG and from 91.6% to 96.4% 
for anti-GP2 IgA. The κ coefficients suggested good concordance 
between the different assays. The exact κ-values are summarised in 
Supplementary Table 1 [available as Supplementary data at ECCO-
JCC online].
4. Discussion
In the present study, we investigated the clinical importance of dif-
ferent target-specific PAbs in the prediction of complicated disease 
behaviour and surgery in adult CD patients. To our knowledge, this 
is the first prospective study on the new PAbs. In addition, we proved 
the long-term stability of PAb status over time and confirmed good 
agreement among newly available diagnostic tools for evaluation of 
anti-GP2 antibodies.
Significantly more CD patients were positive for different PAbs 
compared with both UC patients and healthy controls. The forma-
tion of autoantibodies against GP2 and CUZD1 glycoproteins may 
reflect an immune response against an overwhelming microbial 
challenge to the intestinal barrier. Anti-GP2 antibody titres were 
higher in CD compared with UC as well. The magnitude of antibody 
responses [titres] may correlate with the extent of bacterial translo-
cation [BT], which is more pronounced in CD compared with UC. 
One possible explanation is that in UC the inflammation is confined 
to the mucosa whereas in CD it is transmural. Another explana-
tion might be that the disturbance of mucosal immunity is different 
between the two diseases. It is further supported by the findings that 
the presence of GP2 was confirmed at the intestinal site of inflamma-
tion in patients with CD.32
In previous clinical studies, presence of anti-GP2 antibodies was 
associated with distinct clinical phenotype of CD such as early disease 
onset, ileal involvement, and stricturing disease behavior, but results 
differed among studies. However, in the single study identifying anti-
CUZD1 antibody as a distinct PAb type, the association with clinical 
phenotype or disease course was not assessed in CD.9 Interestingly, 
clinical associations were different for anti-GP2 and anti-CUZD1 
antibodies in the present cohort, which may be at least partly the 
consequence of differences in the target proteins of these antibod-
ies belonging to distinct innate immunity protein families. Prevalence 
of anti-GP2 antibodies was higher in our patients with paediatric 
onset, in concordance with findings of some previous studies.14,15 
Regarding disease location, we were also able to confirm that pres-
ence of anti-GP2 antibodies was associated with extensive disease 
with ileal involvement.14,15,16 Of note, some reports failed to identify 
an association between anti-GP2 antibodies and disease location33 or 
this was limited to only upper gastrointestinal tract involvement.18 
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Figure 2. Kaplan-Meier survival analysis for the probability of resective surgery.
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Anti-CUZD1 antibodies were more frequent in patients with colonic 
involvement. Penetrating disease was associated with anti-GP2 posi-
tivity in the present CD cohort. In the study of Bogdanos et  al.,15 
anti-GP2 IgG were significantly more prevalent in patients with stric-
turing behaviour and perianal disease, but less prevalent in those with 
penetrating behaviour, whereas other studies did not find significant 
association between anti-GP2 antibodies and complicated disease 
behaviour.14,18 Thus far, no study has evaluated associations between 
target-specific PAbs and extraintestinal manifestations. We found that 
PSC was associated with the presence of anti-GP2, whereas cutane-
ous manifestations were associated with anti-CUZD1 antibodies. Of 
note, despite these differences between the clinical phenotypes, the 
concordance among the three assays was good. Each test recognised 
also an additional patient population that was missed by the other[s], 
suggesting partly non-overlapping epitopes.
Our findings support that PAbs may contribute to better stratifi-
cation of CD patients. Prevalence is relatively low, and so the clini-
cal utility of PAbs in the diagnosis and prediction of disease course 
in CD may be more modest compared with ASCA which remains 
the most accurate single marker in CD so far.2 However, anti-GP2 
antibody has been shown to be more specific for CD than ASCA 
recently, and the specificity of double-positive patients with CD is 
100%.14 Of note, the prevalence rate of anti-GP2 IgA/IgG in our CD 
patients was even lower than rates reported previously [10.2–12.4% 
vs 21.0–45.0%].34 Variation in the prevalence of serological mark-
ers among studies and in different ethnic populations is however 
well documented.2 Moreover, methodological differences can also 
contribute to these differences. It is interesting to note that different 
isoforms of GP2 are synthesised in the pancreas.35 A  larger and a 
shorter isoform of GP2 were identified and termed alpha [GP2a] and 
beta [GP2b], respectively.36 Previous prevalence data of anti-GP2 IgA 
and IgG, except one,14 were obtained mainly by assays manufactured 
by GA Generic Assays employing the larger isoform for GP2-specific 
autoantibody detection initially.13 In contrast, both ELISAs used in 
our study employed recombinant human GP2 isoform 4 as solid-
phase antigen corresponding to the shorter isoform [GP2b], because 
of better discrimination of patients with CD from those with UC.35
For the long-term predictive potential of serological markers, it is 
necessary to assess the stability of antibody status over time. In terms 
of anti-GP2 antibody stability, only limited and conflicting data are 
available.17 In the present study, long-term stability of different PAbs 
was assessed extensively. PAb status was not associated with actual 
disease activity, and positivity rates were stable over time in IBD 
patients. This is in contrast to anti-GP2 antibody levels detected in 
patients with coeliac disease where they were significantly reduced 
under a gluten-free diet.3
Until now, only cross-sectional associative analyses have been 
available in CD patients. In addition, the present study provides lon-
gitudinal prospective results on the predictive potential of PAbs for 
identifying disease-specific complications and surgery requirements. 
PAb positivity was able to predict faster progression to complicated 
disease in our patient cohort. Anti-GP2 positivity was associated 
with the need for surgical interventions, and anti-CUZD1 predicted 
development of perianal complications. Regarding anti-GP2, previ-
ously only two cross-sectional studies evaluated surgical outcome, 
with conflicting results.16,18 Of note however, treatment strategy may 
vary among countries, IBD centres and even doctors, which is a clear 
confounder of all studies. Therefore association between serology 
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Figure 3. Kaplan-Meier survival analysis for the probability of perianal disease development.
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and surgical findings in the present study should be interpreted with 
caution. However, one of the main strengths of our study is the 
analysis of outcomes during a prospective follow-up period. The fre-
quency of regular follow-up was 3–6 months in the majority of the 
patients. Silverberg et al.20 suggested that long-term complications 
and outcomes should be studied during an approximate 5-year fol-
low-up. Of note, 79.2% of the CD patients in the present cohort had 
at least a 5years of follow-up. In addition, the collection of extensive 
disease phenotypes enabled adjustment for possible confounders. In 
the final Cox-regression multivariate model, anti-CUZD1 antibody 
positivity was a strong independent predictor for the development of 
perianal complications, including age at diagnosis, sex, disease loca-
tion and behaviour, and relapse frequency as potential confounders. 
Our results await replication in independent patient cohorts both 
from referral centres and from population-based cohorts.
Interestingly, in our study IgA but not IgG PAbs types were 
associated with complicated disease course in CD. The gut mucosal 
immune system plays a central role in the IgA antibody formation, 
and this may at least partly reflect an immune response against an 
overwhelming microbial challenge. In addition, IgA type autoanti-
bodies are considered a sign of immunological response to enteric 
antigens in other diseases associated with enhanced bacterial trans-
location. Moreover, IgA type antibodies were reported to have a 
pivotal role in the development of disease-specific complications 
compared with the IgG antibody subtype.37 Our clinical findings are 
concordance with a previous hypothesis from Roggenbuck et al.12,17 
According to this hypothesis, plasma cells can synthesise anti-GP2 
IgA after the loss of tolerance towards GP2, which will be actively 
transported by the epithelium into the intestinal lumen. Indeed, 
anti-GP2 IgA has been found in faeces of patients with pouchitis 
exhibiting CD-like complications.38 The secreted anti-GP2 IgA can 
bridge FimH-positive bacteria opsonised by pancreatic GP2 with the 
membrane-bound GP2 on the M cells. Ultimately, this may lead to 
a mucosal overload of microbes in CD due to elevated transcytosis 
accelerating intestinal inflammation.
In conclusion, the findings of our prospective referral cohort 
study indicate that target-specific PAbs may be useful markers in the 
stratification of CD patients and are associated with complicated 
disease phenotype and risk of developing perianal complications. In 
addition, they may be valuable additional tools as a member of serol-
ogy panels for the prediction of disease course.
Supplementary material
Supplementary data to this article can be found at ECCO-JCC 
online.
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